Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22967473 | 0.90 | POLB (0.50) | LMNAKMT2ACYP2D6ALDH1A1MAPK1 | |
| SCHEMBL20483621 | 0.89 | TSHR (0.58) | LMNAKMT2ACYP2D6ALDH1A1MAPK1 | |
| SCHEMBL8907465 | 0.89 | TSHR (0.58) | LMNAKMT2ACYP2D6ALDH1A1MAPK1 | |
| SCHEMBL8722654 | 0.84 | TSHR (0.64) | LMNAKMT2ACYP2D6ALDH1A1MAPK1 | |
| SCHEMBL15514610 | 0.84 | TSHR (0.64) | LMNAKMT2ACYP2D6ALDH1A1MAPK1 | |
| SCHEMBL23742930 | 0.84 | TSHR (0.64) | LMNAKMT2ACYP2D6ALDH1A1MAPK1 | |
| SCHEMBL10359936 | 0.84 | TSHR (0.64) | LMNAKMT2ACYP2D6ALDH1A1MAPK1 | |
| SCHEMBL8722653 | 0.84 | TSHR (0.64) | LMNAKMT2ACYP2D6ALDH1A1MAPK1 | |
| SCHEMBL25427235 | 0.83 | CYP2D6 (0.54) | LMNAKMT2ACYP2D6MAPK1TSHR | |
| SCHEMBL15919153 | 0.83 | CYP2D6 (0.54) | LMNAKMT2ACYP2D6MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-16 | — | — | US | disclosed |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-2949665-B1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2949665-A1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014115797-A1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | 第一三共株式会社 (JP) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | NPPA, NPR1, NPR3 | LMNA 1358/4885KMT2A 3687/4885CYP2D6 3766/4885 |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | LMNA 1358/4885KMT2A 3687/4885CYP2D6 3766/4885 |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | LMNA 1358/4885KMT2A 3687/4885CYP2D6 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.